EU/3/05/324:

Levamisole (hydrochloride)

Table of contents

Overview

On 28 October 2005, orphan designation (EU/3/05/324) was granted by the European Commission to ACE Pharmaceuticals BV, The Netherlands, for levamisol hydrochloride for the treatment of nephrotic syndrome.

Key facts

Active substance
Levamisole (hydrochloride)
Intented use
Treatment of nephrotic syndrome
Date of designation
28/10/2005
Orphan designation status
Positive
EU designation number
EU/3/05/324

Sponsor's contact details

ACE Pharmaceuticals BV
Schepenveld 41
3891 ZK Zeewolde
The Netherlands
Telephone: +31 36 522 72 01
Telefax: +31 36 522 9096
E-mail: ace@ace-pharm.nl

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

Related content

How useful was this page?

Add your rating